Menu
Search
|

Menu

Close
X

Sellas Life Sciences Group Inc SLS.OQ (NASDAQ Stock Exchange Capital Market)

1.55 USD
+0.05 (+3.33%)
As of Jul 20
chart
Previous Close 1.50
Open 1.85
Volume 1,764,424
3m Avg Volume 132,319
Today’s High 2.04
Today’s Low 1.51
52 Week High 17.70
52 Week Low 1.38
Shares Outstanding (mil) 6.66
Market Capitalization (mil) 10.18
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
3
EPS (USD)
FY18
-1.674
FY17
-14.515
FY16
-32.495
FY15
-158.422
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.34
Price to Sales (TTM)
vs sector
--
8.11
Price to Book (MRQ)
vs sector
--
4.23
Price to Cash Flow (TTM)
vs sector
--
22.22
Total Debt to Equity (MRQ)
vs sector
--
17.18
LT Debt to Equity (MRQ)
vs sector
--
13.08
Return on Investment (TTM)
vs sector
-140.99
13.18
Return on Equity (TTM)
vs sector
-248.18
15.09

EXECUTIVE LEADERSHIP

Angelos Stergiou
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Gene Mack
Chief Financial Officer, Treasurer, Since 2018
Salary: --
Bonus: --
Nicholas Sarlis
Chief Medical Officer, Senior Vice President, Since 2017
Salary: --
Bonus: --
John Burns
Vice President - Finance, Corporate Controller, Since 2017
Salary: --
Bonus: --
Fabio Lopez
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

315 Madison Ave Frnt 4
NEW YORK   NY   10017-5405

Phone: +1813.8644523

SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.

SPONSORED STORIES